Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD

Management of patients with CKD and HF complicated by hyperkalemia

15' education - Sep. 28, 2023 - Ellie Kelepouris, MD, and Stephen J. Greene, MD

The key role of RAASi therapy in patients with HF

10' education - Sep. 26, 2023 - Shelley Zieroth, MD

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD

Inorganic nitrate reduces risk of contrast-induced nephropathy after coronary angiography

3' education - Sep. 21, 2023 - Dan Jones, MD, PhD

Update of ESC guidelines on heart failure in a nutshell

5' education - Sep. 4, 2023 - Theresa McDonagh, MD

Main messages of new ESC guidelines for CVD management in diabetes

3' education - Aug. 29, 2023 - Nikolaus Marx, MD

Protective renal effects of ARNI in patients with HFmrEF/HFpEF

3' education - Aug. 26, 2023 - Muthiah Vaduganathan, MD

Practical experience and model for optimizing RAASi-based therapy in HF

10' education - July 25, 2023 - Aaron Wong, MD

Polypharmacy: Adding nonsteroidal MRAs, when and how

10' education - July 24, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MD

Optimizing therapy for a patients with T2D and early-stage CKD

10' education - July 20, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MD

Nonsteroidal MRA as a therapeutic option in patients with T2D and CKD

10' education - July 17, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MD

Initiation of SGLT2i in CKD: how, when and who?

10' education - June 27, 2023 - David Cherney, MD, PhD, Roberto Pecoits-Filho, MD, PhD, and Magdalena Madero, MD

Meta-analysis of the effects of SGLT2i on kidney outcomes

10' education - June 19, 2023 - Natalie Staplin, PhD

SGLT2i in the spectrum of CKD: A call for action

10' education - June 1, 2023 - Meg Jardine, MD, PhD

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - May 30, 2023 - Jozine ter Maaten, MD, PhD

The latest evidence of SGLT2i in CKD

10' education - May 16, 2023 - Will Herrington, MD

New opportunities to tackle the global burden of CKD – the role of SGLT2i

10' education - May 9, 2023 - Adeera Levin, MD
4 things to know about CKD and SGLT2i - lecture 4 out of 4

Primary care role in CKD

10' education - Mar. 30, 2023 - Prof. Richard Hobbs, MD
4 things to know about CKD and SGLT2i - lecture 3 out of 4

A call to action: optimizing treatment in CKD

10' education - Mar. 22, 2023 - Prof. Meg Jardine, MD, PhD

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD
4 things to know about CKD and SGLT2i - lecture 2 out of 4

When and how to initiate SGLT2i in CKD

10' education - Feb. 14, 2023 - Prof. David Wheeler, MD
4 things to know about CKD and SGLT2i - lecture 1 out of 4

What is the evidence of SGLT2i in CKD?

10' education - Feb. 7, 2023 - Prof. Hiddo L. Heerspink, PhD

Inflammation as a new target in CV risk reduction

10' education - Dec. 13, 2022 - Prof. Paul Ridker, MD

Optimizing GDMT in HFrEF and management of hyperkalemia

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD

3' education - Nov. 7, 2022 - David Preiss, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification

10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD

Management of patients with CKD and HF complicated by hyperkalemia

15' education - Sep. 28, 2023 - Ellie Kelepouris, MD, and Stephen J. Greene, MD
How are you managing elevated potassium in your patients with HF and CKD? Ellie Kelepouris and Stephen Greene discuss a multidisciplinary approach.

How are you managing elevated potassium in your patients with HF and CKD? Ellie Kelepouris and Stephen Greene discuss a multidisciplinary approach.

The key role of RAASi therapy in patients with HF

10' education - Sep. 26, 2023 - Shelley Zieroth, MD
Shelley Zieroth talks about the importance of continuing foundational therapy in symptomatic HF, despite challenges such as the occurrence of hyperkalemia.

Shelley Zieroth talks about the importance of continuing foundational therapy in symptomatic HF, despite challenges such as the occurrence of hyperkalemia.

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD
Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

FDA approves SGLT2 inhibitor for CKD

News - Sep. 25, 2023

Empagliflozin has been approved by the FDA for the treatment of adults with CKD.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Inorganic nitrate reduces risk of contrast-induced nephropathy after coronary angiography

3' education - Sep. 21, 2023 - Dan Jones, MD, PhD
**ESC Congress 2023** The randomized NITRATE-CIN study found that dietary intake of inorganic nitrate reduced the risk of contrast-induced nephropathy by 70%, and improved renal and cardiovascular outcomes.

ESC Congress 2023 The randomized NITRATE-CIN study found that dietary intake of inorganic nitrate reduced the risk of contrast-induced nephropathy by 70%, and improved renal and cardiovascular outcomes.

Acetazolamide increases successful decongestion in acute decompensated HF irrespective of baseline renal function

News - Sep. 11, 2023

ESC Congress 2023 A prespecified analysis of the ADVOR trial showed that the addition of acetazolamide to loop diuretics increases successful decongestion in patients with acute decompensated HF compared with placebo regardless of baseline renal function.

Greater cardioprotective effects of nonsteroidal MRA in CKD and T2D patients with anemia

News - Sep. 5, 2023

ESC Congress 2023 A post-hoc analysis of FIDELITY showed that baseline anemia status modifies the effect of finerenone on cardiovascular outcomes, but not renal outcomes, in patients with CKD and T2D.

Update of ESC guidelines on heart failure in a nutshell

5' education - Sep. 4, 2023 - Theresa McDonagh, MD
What are the main changes in the 2023 update of the 2021 ESC HF guidelines? Theresa McDonagh presents the changes of three updated sections.

ESC Congress 2023 What are the main changes in the 2023 update of the 2021 ESC HF guidelines? Theresa McDonagh presents the changes of three updated sections.

Main messages of new ESC guidelines for CVD management in diabetes

3' education - Aug. 29, 2023 - Nikolaus Marx, MD
Nikolaus Marx presents the main messages of the 2023 ESC Guidelines for the management of CVD in patients with diabetes.

ESC Congress 2023 Nikolaus Marx presents the main messages of the 2023 ESC Guidelines for the management of CVD in patients with diabetes.

Protective renal effects of ARNI in patients with HFmrEF/HFpEF

3' education - Aug. 26, 2023 - Muthiah Vaduganathan, MD
**ESC Congress 2023** Muthiah Vaduganathan shares the results of a pooled analysis of PARAGLIDE-HF and PARAGON-HF that investigated the effects of sacubitril/valsartan on renal outcomes. “Sacubitril/valsartan has meaningful renal protection compared with the angiotensin receptor blocker valsartan”, says Muthiah Vaduganathan.

ESC Congress 2023 Muthiah Vaduganathan shares the results of a pooled analysis of PARAGLIDE-HF and PARAGON-HF that investigated the effects of sacubitril/valsartan on renal outcomes. “Sacubitril/valsartan has meaningful renal protection compared with the angiotensin receptor blocker valsartan”, says Muthiah Vaduganathan.

ARNI reduces renal outcomes in patients with HFmrEF/HFpEF

News - Aug. 26, 2023

ESC Congress 2023 A prespecified analysis of the PARAGLIDE-HF and PARAGON-HF trials demonstrated that sacubitril/valsartan compared with valsartan reduces the risk of clinically relevant renal outcomes in patients with HFmrEF/HFpEF.